ASH 2025 | Pivekimab sunirine + Ven + Aza in unfit patients with ND CD123+ AML: Phase Ib/II efficacy and safety
AML Hub13 Jan

ASH 2025 | Pivekimab sunirine + Ven + Aza in unfit patients with ND CD123+ AML: Phase Ib/II efficacy and safety

Following the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the AML Hub was pleased to speak with Gail Roboz, Weill Cornell Medicine, New York, US. We asked, What are the latest findings from clinical trials of pivekimab sunirine in unfit patients with newly diagnosed acute myeloid leukemia (AML)?


In this interview, Roboz discusses key findings from a preliminary subgroup analysis of a phase Ib/II trial (NCT04086264), investigating the anti-CD123 antibody–drug conjugate pivekimab sunirine in combination with azacitidine and venetoclax, for ≥14 days or 28 days, in unfit patients with newly diagnosed CD123-positive AML. The primary endpoint was antileukemic activity, including complete remission (CR) and composite CR with incomplete hematologic recovery (CR/CRi) rates.


This educational resource is independently supported by AbbVie. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.

Avsnitt(33)

Know AML webinar | Closing remarks and Q&A

Know AML webinar | Closing remarks and Q&A

Know AML conducted a healthcare professional (HCP) and patient webinar on April 23, 2025, titled ‘Mutation testing in AML: What you need to know’. Here, we share closing remarks and questions from the...

26 Juni 20259min

Know AML webinar | How can physicians and patients communicate more clearly about mutation testing in AML going forward?

Know AML webinar | How can physicians and patients communicate more clearly about mutation testing in AML going forward?

This independent educational activity is supported by Thermo Fisher Scientific. All content is developed independently by the faculty. The funder is allowed no influence on the content. Know AML hoste...

19 Juni 20259min

Know AML webinar | Empowering patients to ask their physician the right questions during their AML journey

Know AML webinar | Empowering patients to ask their physician the right questions during their AML journey

Know AML hosted a webinar for patients and healthcare professionals (HCPs) on April 23, 2025, titled ‘Mutation testing in AML: What you need to know’. Here, we share a discussion between Gail J. Roboz...

13 Juni 202527min

Know AML webinar | What are mutations, and why do they matter in AML?

Know AML webinar | What are mutations, and why do they matter in AML?

Know AML hosted a webinar for patients and healthcare professionals (HCPs) on April 23, 2025, titled ‘Mutation testing in AML: What you need to know’. Here, we share a presentation by the chair, Charl...

9 Juni 202513min

“How I treat” a patient with DNMT3A-mutated AML in remission post intensive chemotherapy

“How I treat” a patient with DNMT3A-mutated AML in remission post intensive chemotherapy

The AML Hub was pleased to speak with Cristina Papayannidis, Universitaria di Bologna, Bologna, IT. We asked, How do you treat a patient with DNMT3A-mutated acute myeloid leukemia (AML) in remission p...

3 Okt 20245min

CPX-351 as first-line treatment in AML: Real-world data

CPX-351 as first-line treatment in AML: Real-world data

Here, we summarize five real-world studies presented at EHA 2024 on real-world outcomes of patients with AML who received CPX-351 as a first-line treatment. Hosted on Acast. See acast.com/privacy fo...

30 Sep 202416min

What is the impact of the 5th WHO classification and ICC of AML on diagnosis and treatment of high-risk AML​?

What is the impact of the 5th WHO classification and ICC of AML on diagnosis and treatment of high-risk AML​?

The AML Hub was pleased to speak with Gail Roboz, Weill Cornell Medicine, New York, US. We asked, What is the impact of the 5th World Health Organization (WHO) classification and International Consens...

17 Sep 202413min

What were your highlights from ASH 2023?

What were your highlights from ASH 2023?

During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, Michal Bar-Natan, Weill Cornell Medicine, New York, US, shared her highlights with the AML Hub. Hosted on Acast. Se...

29 Apr 20243min

Populärt inom Utbildning

rss-bara-en-till-om-missbruk-medberoende-2
historiepodden-se
det-skaver
nu-blir-det-historia
alska-oss
sektledare
harrisons-dramatiska-historia
allt-du-velat-veta
johannes-hansen-podcast
rss-viktmedicinpodden
rss-sjalsligt-avkladd
not-fanny-anymore
rss-max-tant-med-max-villman
roda-vita-rosen
sa-in-i-sjalen
i-vantan-pa-katastrofen
rikatillsammans-om-privatekonomi-rikedom-i-livet
rss-npf-podden
rss-basta-livet
sex-pa-riktigt-med-marika-smith